TY - JOUR
T1 - Expanding relevance of aortic valve repair - Is earlier operation indicated?
AU - Sharma, Vikas
AU - Suri, Rakesh M.
AU - Dearani, Joseph A.
AU - Burkhart, Harold M.
AU - Park, Soon J.
AU - Joyce, Lyle D.
AU - Li, Zhuo
AU - Schaff, Hartzell V.
N1 - Funding Information:
Disclosures: The Division of Cardiovascular Surgery has a research grant titled “Randomized biological aortic valve replacement” funded equally by Edwards LifeSciences, St Jude Medical, and the Sorin Group. Dr Suri is the Principal Investigator for the PERCEVAL™ Investigational Device Exemption trial funded by the Sorin Group . Dr Park has served on the advisory board of Thoratec and as the course director for a Cleveland Clinic conference. None of the disclosures pertain to the current investigation. All other authors have nothing to disclose with regard to commercial support.
PY - 2014/1
Y1 - 2014/1
N2 - Objectives: To define the durability of aortic valve repair (AVR ep) and the effect of surgical timing on late survival. Methods: From June 1986 to June 2011, 331 patients underwent elective AVRep for aortic regurgitation (mean age, 53 ± 17 years; 76% men). The repair methods included commissuroplasty (n = 270; 81%), triangular resection and plication (n = 106; 32%), resuspension or cusp shortening (n = 102; 31%), and perforation closure (n = 23; 7%). Results: In-hospital mortality was 0.6% (2 of 332). Four patients (1%) experienced early repair failure; two underwent repeat repair. Overall survival was 91% and 81% at 5 and 10 years, respectively. After adjusting for age, greater left ventricular end-systolic dimension (per 5 mm; hazard ratio [HR], 1.49; 95% confidence interval [CI], 1.23-1.79; P <.001) and lower ejection fraction (per 5%; HR, 1.42; 95% CI, 1.25-1.63; P ≤.001) were significant predictors of long-term mortality. Patients with ejection fraction < 50% and left ventricular end-systolic dimension > 50 mm had significantly greater odds of late death (HR, 3.46; 95% CI, 2.05-5.82; P <.001 and HR, 2.08; 95% CI, 1.05-4.12; P =.036, respectively). The risk of aortic valve reoperation was 10% and 21% at 5 and 10 years, respectively. The presence of severe aortic regurgitation (HR, 2.2; 95% CI, 1.1-5.06; P =.02) and more than mild regurgitation at discharge (HR, 5.87; 95% CI, 2.67-12.68; P ≤.0001) were predictors of late reoperation. Freedom from other valve-related events was 94% and 91% at 5 and 10 years, respectively. Forty-seven patients (21%) with intact valve repair were using warfarin at the last follow-up visit. Conclusions: AVRep can be performed with excellent late survival and freedom from valve-related events. Awaiting the onset of ventricular dysfunction increases the risk of late mortality, warranting earlier consideration of AVRep for patients with suitable anatomy.
AB - Objectives: To define the durability of aortic valve repair (AVR ep) and the effect of surgical timing on late survival. Methods: From June 1986 to June 2011, 331 patients underwent elective AVRep for aortic regurgitation (mean age, 53 ± 17 years; 76% men). The repair methods included commissuroplasty (n = 270; 81%), triangular resection and plication (n = 106; 32%), resuspension or cusp shortening (n = 102; 31%), and perforation closure (n = 23; 7%). Results: In-hospital mortality was 0.6% (2 of 332). Four patients (1%) experienced early repair failure; two underwent repeat repair. Overall survival was 91% and 81% at 5 and 10 years, respectively. After adjusting for age, greater left ventricular end-systolic dimension (per 5 mm; hazard ratio [HR], 1.49; 95% confidence interval [CI], 1.23-1.79; P <.001) and lower ejection fraction (per 5%; HR, 1.42; 95% CI, 1.25-1.63; P ≤.001) were significant predictors of long-term mortality. Patients with ejection fraction < 50% and left ventricular end-systolic dimension > 50 mm had significantly greater odds of late death (HR, 3.46; 95% CI, 2.05-5.82; P <.001 and HR, 2.08; 95% CI, 1.05-4.12; P =.036, respectively). The risk of aortic valve reoperation was 10% and 21% at 5 and 10 years, respectively. The presence of severe aortic regurgitation (HR, 2.2; 95% CI, 1.1-5.06; P =.02) and more than mild regurgitation at discharge (HR, 5.87; 95% CI, 2.67-12.68; P ≤.0001) were predictors of late reoperation. Freedom from other valve-related events was 94% and 91% at 5 and 10 years, respectively. Forty-seven patients (21%) with intact valve repair were using warfarin at the last follow-up visit. Conclusions: AVRep can be performed with excellent late survival and freedom from valve-related events. Awaiting the onset of ventricular dysfunction increases the risk of late mortality, warranting earlier consideration of AVRep for patients with suitable anatomy.
UR - http://www.scopus.com/inward/record.url?scp=84890553030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890553030&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2013.08.015
DO - 10.1016/j.jtcvs.2013.08.015
M3 - Article
C2 - 24084289
AN - SCOPUS:84890553030
SN - 0022-5223
VL - 147
SP - 100
EP - 108
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 1
ER -